| Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment. | |
| | |
MedLine Citation:
|
PMID: 1568347 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The aim of the study was to determine whether growth hormone (GH) treatment decreased net protein catabolism of lean tissues in patients receiving chronic glucocorticoid treatment. DESIGN: Whole body leucine kinetics were measured in post-absorptive conditions using a 1-14C-leucine infusion before and during GH administration (0.0125 mg/kg/day; 0.033 U/kg/day) for 7 days. PATIENTS: We studied four patients (age range 31-71 years) who had taken prednisone (mean +/- SEM 0.21 +/- 0.03 mg/kg/day, total dose 10-27.5 mg/day) for longer than 5 months for various lung diseases. RESULTS: During GH treatment leucine oxidation decreased (baseline 0.44 +/- 0.07 vs GH 0.37 +/- 0.05 mumol/kg lean body mass/min, P = 0.01) and non-oxidative leucine disposal increased (1.95 +/- 0.10 vs 2.05 +/- 0.09 mumol/kg lean body mass/min, P = 0.02) but leucine appearance was unaltered. CONCLUSIONS: We conclude that GH decreased amino acid catabolism and improved protein synthesis without altering protein breakdown in patients receiving chronic glucocorticoid treatment. There may be a role for GH in mitigating the protein catabolic side-effects of prolonged glucocorticoid treatment. |
| | |
Authors:
|
W M Bennet; M W Haymond |
Related Documents
:
|
10754477 - The gh response to low-dose bolus growth hormone-releasing hormone (ghrh(1-29)nh2) is a... 9920537 - The duration of response to norgestimate and ethinyl estradiol in the treatment of acne... 8852867 - Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men. 2444447 - The modulating effect of estrogens on luteinizing hormone release in complete androgen ... 9832227 - Diclofenac analgesia following cleft palate surgery. 21945167 - Dosimetric evaluation of a three-phase adaptive radiotherapy for nasopharyngeal carcino... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Clinical endocrinology Volume: 36 ISSN: 0300-0664 ISO Abbreviation: Clin. Endocrinol. (Oxf) Publication Date: 1992 Feb |
Date Detail:
|
Created Date: 1992-05-22 Completed Date: 1992-05-22 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0346653 Medline TA: Clin Endocrinol (Oxf) Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 161-4 Citation Subset: IM |
Affiliation:
|
Endocrine Research Unit, Mayo Clinic and Foundation, Rochester, MN 55905. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Body Composition
/
drug effects Caproates / blood Female Growth Hormone / therapeutic use* Humans Keto Acids / blood Leucine / metabolism Lung Diseases / blood, drug therapy*, metabolism Male Middle Aged Nitrogen / metabolism Prednisolone / therapeutic use* Proteins / metabolism* Time Factors |
| Grant Support | |
ID/Acronym/Agency:
|
DK-26989/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Caproates; 0/Keto Acids; 0/Proteins; 50-24-8/Prednisolone; 61-90-5/Leucine; 7727-37-9/Nitrogen; 816-66-0/alpha-ketoisocaproic acid; 9002-72-6/Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A retrospective audit of the combined pituitary function test, using the insulin stress test, TRH an...
Next Document: Rate of change (modulation) of serum growth hormone concentrations is a more important factor in det...